Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.
BACKGROUND
Cardiovascular disease (CVD) is the main cause of death among hemodialysis (HD) patients. The effects of the dipeptidyl peptidase-4 inhibitor teneligliptin on CVD-related biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving HD treatment are poorly understood. To determine whether teneligliptin has anti-CVD properties, we assessed its effects on soluble P-selectin (sP-selectin), platelet-derived microparticles (PDMPs), plasminogen activator inhibitor 1 (PAI-1), soluble E-selectin (sE-selectin), soluble vascular adhesion molecule 1 (sVCAM-1), and adiponectin plasma levels in HD and non-HD patients with T2DM.


METHODS
Patients with T2DM eligible for teneligliptin monotherapy or combination therapy (eg, teneligliptin plus a sulfonylurea) were administered teneligliptin (20 mg/d) once daily for 6 months. Plasma levels of sP-selectin, PDMPs, PAI-1, sE-selectin, sVCAM-1, and adiponectin were measured by enzyme-linked immunosorbent assay at baseline and after 3 months and 6 months of treatment.


RESULTS
Teneligliptin therapy significantly reduced plasma levels of sP-selectin, PDMPs, and PAI-1 compared with baseline levels, while significantly increasing adiponectin levels. sE-selectin and sVCAM-1 levels were significantly decreased only at 6 months. The reduction in sP-selectin, PDMPs, and PAI-1 was more significant in HD patients than in non-HD patients. However, the improvement in adiponectin levels was unchanged with HD treatment.


CONCLUSIONS
By modulating PDMPs or PAI-1, teneligliptin shows an antiatherothrombotic effect that may be beneficial in the primary prevention of CVD in patients with T2DM on HD.
Division of Internal Medicine, Meisei Memorial Hospital, Osaka, Japan.
Yoshinori
Y
Okuda
Division of Internal Medicine, Kohrigaoka Yukeikai Hospital, Osaka, Japan.
Seitaro
S
Omoto
Division of Internal Medicine, Daiwa Hospital, Osaka, Japan.
Takehito
T
Taniura
Division of Internal Medicine, Saiseikai Izuo Hospital, Osaka, Japan.
Akira
A
Shouzu
First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Shosaku
S
Nomura
PAI-1; PDMP; hemodialysis; teneligliptin; type 2 diabetes mellitus